-+ 0.00%
-+ 0.00%
-+ 0.00%
Immuneering Appoints Grant Bogle to Board of Directors
Share
Listen to the news
Immuneering Appoints Grant Bogle to Board of Directors
  • Immuneering appointed Grant Bogle to its board of directors, effective November 9, 2026.
  • Bogle most recently served on Nuvalent's board; his prior roles include Epizyme CEO and TESARO chief commercial officer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090730PRIMZONEFULLFEED9872407) on November 09, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending